Letters

Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7555.1451-b (Published 15 June 2006) Cite this as: BMJ 2006;332:1451
  1. Enrique J Sánchez-Delgado, professor (esanchez@metropolitano.com.ni)
  1. Hospital Metropolitano Vivian Pellas, Managua, Nicaragua

    EDITOR—The paper by Kearney et al on the risk of atherothrombosis with cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) supports the data of Hippisley-Cox et al, who revised the gastrointestinal risks of these drugs.1 2


    Embedded Image

    A clear picture is forming, that the risks and benefits are determined by doses and potencies more than by their selectivity to the cyclo-oxygenases, with the exception of low dose aspirin, which permanently inhibits platelet …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe